Cardiovascular Systems to Present at Upcoming Investor Conferences
February 24 2011 - 4:11PM
Business Wire
Cardiovascular Systems, Inc. (Nasdaq: CSII), a medical device
company developing and commercializing innovative, interventional
treatment systems for vascular disease, will present at two
upcoming health care conferences: the Citi 2011 Global Health Care
Conference at the Hilton New York Hotel, and the RBC Capital
Markets Health Care Conference at the Palace Hotel, both in New
York. President and Chief Executive Officer David L. Martin will
provide an overview of the company and its growth opportunities at
the Citi conference and will participate in the Innovations in
Cardiovascular Devices panel at the RBC conference.
WHEN:
Citi 2011 Global Health Care
Conference
Tuesday, March 1; 11 a.m. EST Hilton New York Hotel New York
RBC Capital Markets Health Care
Conference
Wednesday, March 2; 1:35 p.m. EST Palace Hotel New York
WEBCAST:
To listen to a live webcast of either
presentation, go to the investor information section of the
company’s website, www.csi360.com, and click on the respective
webcast icon. The RBC webcast will be audio only. Both webcasts
will be archived for 30 days after the conclusion of Cardiovascular
Systems’ live presentations.
If you have any difficulty accessing the webcast, please
contact
Mick Forgey: (612) 455-1789;
mforgey@psbpr.com
About Cardiovascular Systems, Inc.
Cardiovascular Systems, Inc., based in St. Paul, Minn., is a
medical device company focused on developing and commercializing
interventional treatment systems for vascular disease. The
company’s Diamondback 360® and Diamondback Predator 360°™ PAD
Systems treat calcified and fibrotic plaque in arterial vessels
throughout the leg in a few minutes of treatment time, and address
many of the limitations associated with existing surgical, catheter
and pharmacological treatment alternatives. As many as 12 million
Americans suffer from peripheral arterial disease (PAD), which is
caused by the accumulation of plaque in peripheral arteries
(commonly the pelvis or leg) reducing blood flow. Symptoms include
leg pain when walking or at rest, and can lead to tissue loss and
eventually limb amputation. In August 2007, the U.S. FDA granted
510(k) clearance for the use of the Diamondback 360° as a therapy
for PAD, and CSI commenced a U.S. product launch in September 2007.
Since then, more than 37,000 procedures have been performed using
the Diamondback 360° in leading institutions across the United
States. For more information visit the company’s Web site at
www.csi360.com.
Cardiovascular Systems (NASDAQ:CSII)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cardiovascular Systems (NASDAQ:CSII)
Historical Stock Chart
From Jul 2023 to Jul 2024